Vita34 ApS: Financial statements 2023
CVR: 27511759
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Vita34 ApS (CVR 27511759) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 5,083,920 and a net result of DKK 2,051,465 compared with DKK 5,146,487 the year before. That is a decrease of 35.2% compared with the year before. Equity in the 2023 report amounted to DKK 3,918,676. The solvency ratio was 21.6%.
- Gross Profit
- DKK 5,083,920
- Profit/Loss
- DKK 2,051,465
- Equity
- DKK 3,918,676
- Total Assets
- DKK 18,160,046
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 5.1M | 2.1M | 3.9M | 0 |
| 2022 | - | 7.9M | 5.1M | 1.9M | 0 |
| 2021 | - | 5.2M | 2.7M | -3.3M | 0 |
| 2020 | - | 5.2M | 2.6M | -6M | 0 |
| 2019 | - | 2.4M | -231K | -8.6M | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Vita34 ApS has published its annual report for 2022. Gross profit came to DKK 7,850,419, and the net result was DKK 5,146,487.
About Vita34 ApS
Vita34 ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2004. The company is registered under the industry Drift af sundhedsvæsen i øvrigt i.a.n.. The company was previously named StemCare ApS and BIOBANK DANMARK ApS. The management consists of Marion Bartel and Vivien Weise. The company is owned by FamiCord AG. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 3,842,095 and a net result of DKK 1,034,065 compared with DKK 1,030,138 the year before. Equity in the 2025 report amounted to DKK 5,982,880.